High Throughput Leukemia Diagnosis

高通量白血病诊断

• 批准号: 6690063
• 负责人: JIAN HAN
• 金额: $ 9.87万
• 依托单位: GENACO BIOMEDICAL PRODUCTS, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-15 至 2004-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6690063
• 关键词: cell line; chromosome translocation; clinical research; diagnosis design /evaluation; diagnosis quality /standard; gene expression; genetic screening; high throughput technology; leukemia; neoplasm /cancer diagnosis; polymerase chain reaction; reagent /indicator; technology /technique development

DESCRIPTION (provided by applicant): Recurrent chromosome translocations in leukemias are useful cytogenetic markers for monitoring diagnosis, prognosis and treatment. Traditional cytogenetic study cannot recognize all the gene rearrangements at the molecular level. Also, it is a time consuming and labor intensive procedure. We have developed a proprietary technology that will allow high throughput screening and detection of multiple translocations at a time. The technology, ROCASH (for Reporter Oligo Capturing After Specific Hybridization), utilizes a labeled reporter oligo to study target nucleic acid in a two-step hybridization procedure. The advantages of this method are increased specificity and sensitivity. The end user will not need to perform labeling of the samples. Luminex xMAP technology is used as a platform for this procedure. It can investigate up do 50 genes in one assay. In this feasibility study, four common recurrent translocations will be studied. The long-term goal of this proposed project is to develop a user-friendly reagent kit that will allow the screening of all the genes involved in recurrent chromosome translocations. The kit will be usefuL in diagnosis, molecular classification of the leukemias, prognosis, and treatment monitoring.

描述（由申请人提供）：白血病中反复发生的染色体易位是用于监测诊断、预后和治疗的有用细胞遗传学标记。传统的细胞遗传学研究无法在分子水平上识别所有的基因重排。而且，这是一个耗时且劳动密集的过程。我们开发了一项专有技术，可以一次对多个易位进行高通量筛选和检测。该技术名为 ROCASH（特异性杂交后捕获报告寡核苷酸），利用标记的报告寡核苷酸在两步杂交过程中研究目标核酸。该方法的优点是增加了特异性和灵敏度。最终用户无需对样品进行标记。 Luminex xMAP 技术用作此过程的平台。它可以在一次检测中研究多达 50 个基因。在本可行性研究中，将研究四种常见的经常性易位。该拟议项目的长期目标是开发一种用户友好的试剂盒，可以筛选与反复染色体易位有关的所有基因。该试剂盒将有助于白血病的诊断、分子分类、预后和治疗监测。